Long-term safety study of elismetrep for acute migraine attacks
Tests elismetrep, taken as needed, for safety in adults with migraine.
Key facts
- Who runs it
- TriGemX Bio, Inc.
- Where
- Albuquerque, Allentown, Amherst, Ann Arbor, Atlanta, Austin, Bardstown, Birmingham, Boston, Bountiful, Brooklyn, Centennial, Chalmette, Chandler, Charlotte, Chattanooga, Chicago, City of Saint Peters, Colorado Springs, Colton, Columbus, Commack, Culver City, Cypress, Dallas, Draper, Edmond, Encino, Flossmoor, Fort Collins, Greensboro, Gulfport, Hazelwood, Houston, Irvine, Kansas City, Kenosha, Lampasas, Las Vegas, Lexington, Little Rock, Los Angeles, Manlius, Marietta, Milford, Minneapolis, Mission Viejo, Mobile, Morgantown, Naperville, Nashville, New Orleans, New York, Newport News, Norfolk, North Charleston, North Las Vegas, Oceanside, Ogden, Oklahoma City, Overland Park, Philadelphia, Pikesville, Pittsburgh, Plano, Pomona, Portland, Raleigh, Reno, Ridgeland, Riverside, Riverton, Rochester, Salt Lake City, San Diego, Scottdale, Seattle, Shelby, Sherman Oaks, Smithfield, Spring Valley, Springfield, St Louis, Stockbridge, Tulsa, Walnut Creek, Waltham, Waterbury, Waxahachie, West Chester, West Covina, West Des Moines, West Hills, Wichita, Williamsville, and Yukon, United StatesSee the 112 sites
- Trial code
- Registry title
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,000 people, planned
- Started
- 3 Aug 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Elismetrep
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who finished the earlier elismetrep acute treatment study (K-304 P003). It checks the long-term safety of using elismetrep when a migraine attack occurs.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Acute migraine. People must have treated a qualifying migraine attack in the earlier elismetrep study.
- Earlier treatment
- Must have completed the earlier elismetrep acute treatment study (K-304 P003) and attended its end-of-study visit within the allowed window.
Main reasons for not taking part
- Pregnant, breast-feeding, or planning pregnancy during the study
- A serious adverse event in the earlier study, or an ongoing adverse event at Visit 1
- Imminent risk of self-harm or of harm to others
- Major surgery planned during the trial
- Took part in this trial before
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Participant completing an acute treatment trial of elismetrep (Study K-304 P003; attending the EoS Visit 3 within the allowed visit window of the acute treatment study), treated a qualifying migraine in that study, was at least 80% compliant with the daily e-Diary 'check-ins' in the base study and completed the 2-hour and 4-hour post-dose assessments in the eDiary; Note: If a subject treats their qualifying migraine in the base study within 5 days of randomization (i.e. ≤ 4 daily check-ins should have been completed in the eDiary), they are eligible for this study if they missed 1 daily check-in, even though compliance was <80%
- Participant voluntarily agrees to participate in the study by giving written informed consent
- Participant is able to read, understand, and complete the study questionnaires and diary
- Participant is willing and able to comply with the study schedule of visits, all trial procedures and restrictions
- Participant is willing to use his/her own personal, qualified smartphone to download any specific eDiary applications for use for the entire duration of the study
- For females of reproductive potential (as determined in the base study), continues to agree to remain abstinent from heterosexual activity or a. Agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the EoS visit; Acceptable methods of birth control are:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal. ii. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral; injectable; implantable; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomized partner; sexual abstinence*; progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide; a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)
- Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception
Who cannot take part
- Participant is currently in violation of study requirements for prohibited and permissible concomitant medications or treatments (not already specified in other criteria) or is anticipated to violate these requirements during trial participation) as assessed for the base study E0S/Visit 3
- Has any major surgery scheduled for the duration of the trial
- Has previous participation in this trial. Participation is defined as signed informed consent following completion of the base study EoS/Visit 3 procedures
- Has, at the time of the base study EoS/Visit 3, had any change in medical history or a laboratory finding since screening in the acute treatment study that in the opinion of the investigator renders the participant unsuitable for this study (e.g., development of a finding that would have precluded participation in the base acute treatment study)
- Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the study. Note: Participants must have a negative urine pregnancy result at the base study EoS/Visit 3 (i.e., pre-randomization for this study)
- Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS) taken during the base study E0S/Visit 3, or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in 'since last version' version of the C-SSRS
- Has any other unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with the interpretation of efficacy and/or safety results
- At Visit 1, has an open/ongoing adverse event from the base study EoS visit
- Experienced a serious adverse event in the base study
Where in United States
- Albuquerque Clinical TrialsAlbuquerque, United StatesContact: Annemarie VanceTaking people
- Lehigh Center for Clinical ResearchAllentown, United StatesContact: Annemarie VanceTaking people
- Dent Neuro Institute, BuffaloAmherst, United StatesContact: Annemarie VanceTaking people
- Michigan Headache Pain & Neurological InstituteAnn Arbor, United StatesContact: Annemarie VanceTaking people
- DelRicht ResearchAtlanta, United StatesContact: Annemarie VanceTaking people
- FutureSearch Trials of NeurologyAustin, United StatesContact: Annemarie VanceTaking people
- Tekton ResearchAustin, United StatesContact: Annemarie VanceTaking people
- Physicians to Children & Adolescents, PSC (Kentucky Pediatric / Adult Research)Bardstown, United StatesContact: Annemarie VanceTaking people
- Central Research Associates, LLC (CRA) dba Flourish ResearchBirmingham, United StatesContact: Annemarie VanceTaking people
- Boston Clinical Trials - AlcanzaBoston, United StatesContact: Annemarie VanceTaking people
- Pantheon Clinical ResearchBountiful, United StatesContact: Annemarie VanceTaking people
- SPRI Clinical Trials, LLCBrooklyn, United StatesContact: Annemarie VanceTaking people
- IMMUNOe Research CentersCentennial, United StatesContact: Annemarie VanceTaking people
- Crescent City Headache & Neurology CenterChalmette, United StatesContact: Annemarie VanceTaking people
- TrialSphereChandler, United StatesContact: Annemarie VanceTaking people
- OnSite Clinical SolutionsCharlotte, United StatesContact: Annemarie VanceTaking people
- WR-ClinSearch, LLCChattanooga, United StatesContact: Annemarie VanceTaking people
- Cedar Crosse Research CenterChicago, United StatesContact: Annemarie VanceTaking people
- Chicago Headache Center & Research InstituteChicago, United StatesContact: Annemarie VanceTaking people
- StudyMetrix ResearchCity of Saint Peters, United StatesContact: Annemarie VanceTaking people
- MCB Clinical Research CentersColorado Springs, United StatesContact: Annemarie VanceTaking people
- Axiom Research, LLCColton, United StatesContact: Annemarie VanceTaking people
- Hometown ResearchColumbus, United StatesContact: Annemarie VanceTaking people
- True North NeurologyCommack, United StatesContact: Annemarie VanceTaking people
- ProScience Research GroupCulver City, United StatesContact: Annemarie VanceTaking people
- APD Clinical ResearchCypress, United StatesContact: Annemarie VanceTaking people
- Horizon Clinical Research and Gill NeuroscienceCypress, United StatesContact: Annemarie VanceTaking people
- FutureSearch Trials of Dallas, LPDallas, United StatesContact: Annemarie VanceTaking people
- J. Lewis Research, Inc. / Foothill Family Clinic DraperDraper, United StatesContact: Annemarie VanceTaking people
- OK Clinical Research, LLCEdmond, United StatesContact: Annemarie VanceTaking people
- Leading Edge Research LA, LLCEncino, United StatesContact: Annemarie VanceTaking people
- Healthcare Research Network II, LLCFlossmoor, United StatesContact: Annemarie VanceTaking people
- Advanced Neurosciences ResearchFort Collins, United StatesContact: Annemarie VanceTaking people
- Guilford Neurologic Research Partners, LLCGreensboro, United StatesContact: Annemarie VanceTaking people
- Headache Wellness CenterGreensboro, United StatesContact: Annemarie VanceTaking people
- DelRicht ResearchGulfport, United StatesContact: Annemarie VanceTaking people
- Healthcare Research NetworkHazelwood, United StatesContact: Annemarie VanceTaking people
- DM Clinical ResearchHouston, United StatesContact: Annemarie VanceTaking people
- Victorium Clinical ResearchHouston, United StatesContact: Annemarie VanceTaking people
- Axiom Research, Orange CountyIrvine, United StatesContact: Annemarie VanceTaking people
- AMR Clinical - Kansas CityKansas City, United StatesContact: Annemarie VanceTaking people
- Clinical Investigation Specialists, Inc.Kenosha, United StatesContact: Annemarie VanceTaking people
- GMG Clinical Research, LLC dba Radiance Clinical ResearchLampasas, United StatesContact: Annemarie VanceTaking people
- AMR Clinical - Las VegasLas Vegas, United StatesContact: Annemarie VanceTaking people
- Excel Clinical ResearchLas Vegas, United StatesContact: Annemarie VanceTaking people
- IMA Clinical Research - Las VegasLas Vegas, United StatesContact: Annemarie VanceTaking people
- Redbird ResearchLas Vegas, United StatesContact: Annemarie VanceTaking people
- Wake Research Las Vegas RainbowLas Vegas, United StatesContact: Annemarie VanceTaking people
- AMR Clinical - LexingtonLexington, United StatesContact: Annemarie VanceTaking people
- CTI Clinical Research CenterLexington, United StatesContact: Annemarie VanceTaking people
- Arkansas Clinical ResearchLittle Rock, United StatesContact: Annemarie VanceTaking people
- Clinical Research InstituteLos Angeles, United StatesContact: Annemarie VanceTaking people
- Downtown L.A. Research Center, Inc.Los Angeles, United StatesContact: Annemarie VanceTaking people
- Central New York Clinical ResearchManlius, United StatesContact: Annemarie VanceTaking people
- Drug Studies AmericaMarietta, United StatesContact: Annemarie VanceTaking people
- Hometown ResearchMilford, United StatesContact: Annemarie VanceTaking people
- Clinical Research InstituteMinneapolis, United StatesContact: Annemarie VanceTaking people
- M3 Wake Research - Mission Mental Health (WR-MMH)Mission Viejo, United StatesContact: Annemarie VanceTaking people
- AMR MobileMobile, United StatesContact: Annemarie VanceTaking people
- Frontier Clinical ResearchMorgantown, United StatesContact: Annemarie VanceTaking people
- Chicago Headache Center & Research InstituteNaperville, United StatesContact: Annemarie VanceTaking people
- Access Clinical Trials, IncNashville, United StatesContact: Annemarie VanceTaking people
- Clinical Research Associates, Inc.Nashville, United StatesContact: Annemarie VanceTaking people
- Delricht ResearchNew Orleans, United StatesContact: Annemarie VanceTaking people
- Fieve Clinical Research, IncNew York, United StatesContact: Annemarie VanceTaking people
- Health Research of Hampton Roads, Inc. (HRHR)Newport News, United StatesContact: Annemarie VanceTaking people
- AMR Clinical - NorfolkNorfolk, United StatesContact: Annemarie VanceTaking people
- Coastal Carolina Research CenterNorth Charleston, United StatesContact: Annemarie VanceTaking people
- Las Vegas Clinical TrialsNorth Las Vegas, United StatesContact: Annemarie VanceTaking people
- Excell ResearchOceanside, United StatesContact: Annemarie VanceTaking people
- Advanced Research InstituteOgden, United StatesContact: Annemarie VanceTaking people
- Hightower ClinicalOklahoma City, United StatesContact: Annemarie VanceTaking people
- Clinical Associates Midwest, LLCOverland Park, United StatesContact: Annemarie VanceTaking people
- Collective Medical ResearchOverland Park, United StatesContact: Annemarie VanceTaking people
- Clinical Research PhiladelphiaPhiladelphia, United StatesContact: Annemarie VanceTaking people
- Headlands Research PharmasitePikesville, United StatesContact: Annemarie VanceTaking people
- Preferred Primary Care Physicians, Inc.Pittsburgh, United StatesContact: Annemarie VanceTaking people
- Aim Trials, LLCPlano, United StatesContact: Annemarie VanceTaking people
- Empire Clinical ResearchPomona, United StatesContact: Annemarie VanceTaking people
- The Neurology GroupPomona, United StatesContact: Annemarie VanceTaking people
- Advanced Research Institute - PortlandPortland, United StatesContact: Annemarie VanceTaking people
- Summit Research NetworkPortland, United StatesContact: Annemarie VanceTaking people
- Eximia Research - NC, LLCRaleigh, United StatesContact: Annemarie VanceTaking people
- Advanced Research Institute - RenoReno, United StatesContact: Annemarie VanceTaking people
- Proven EndpointsRidgeland, United StatesContact: Annemarie VanceTaking people
- Artemis Institute for Clinical ResearchRiverside, United StatesContact: Annemarie VanceTaking people
- Granger Medical ClinicRiverton, United StatesContact: Annemarie VanceTaking people
- Rochester Clinical ResearchRochester, United StatesContact: Annemarie VanceTaking people
- J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United StatesContact: Annemarie VanceTaking people
- Acclaim Clinical ResearchSan Diego, United StatesContact: Annemarie VanceTaking people
- Frontier Clinical Research, LLCScottdale, United StatesContact: Annemarie VanceTaking people
- Seattle Clinical Research CenterSeattle, United StatesContact: Annemarie VanceTaking people
- Carolina Research Center, IncShelby, United StatesContact: Annemarie VanceTaking people
- CenExel Sherman Oaks CA (California Neuroscience Research)Sherman Oaks, United StatesContact: Annemarie VanceTaking people
- Frontier Clinical Research, LLCSmithfield, United StatesContact: Annemarie VanceTaking people
- Encompass Clinical ResearchSpring Valley, United StatesContact: Annemarie VanceTaking people
- Clinvest Headlands LLCSpringfield, United StatesContact: Annemarie VanceTaking people
- Sundance Clinical ResearchSt Louis, United StatesContact: Annemarie VanceTaking people
- Sleep Care Research Institute d/b/a Clinical Research Atlanta-StockbridgeStockbridge, United StatesContact: Annemarie VanceTaking people
- DelRicht ResearchTulsa, United StatesContact: Annemarie VanceTaking people
- Diablo Clinical ResearchWalnut Creek, United StatesContact: Annemarie VanceTaking people
- Sunwise Clinical ResearchWalnut Creek, United StatesContact: Annemarie VanceTaking people
- MedVadis Research Corporation, LLCWaltham, United StatesContact: Annemarie VanceTaking people
- Chase Medical Research, LLCWaterbury, United StatesContact: Annemarie VanceTaking people
- Clinpoint TrialsWaxahachie, United StatesContact: Annemarie VanceTaking people
- CincyScienceWest Chester, United StatesContact: Annemarie VanceTaking people
- Kinetic Clinical ResearchWest Covina, United StatesContact: Annemarie VanceTaking people
- Integrated Clinical Trials SolutionWest Des Moines, United StatesContact: Annemarie VanceTaking people
- Focus Clinical ResearchWest Hills, United StatesContact: Annemarie VanceTaking people
- Heartland Research Associates, LLC - An AMR CompanyWichita, United StatesContact: Annemarie VanceTaking people
- Upstate Clinical Research AssociatesWilliamsville, United StatesContact: Annemarie VanceTaking people
- Tekton Research, Inc.Yukon, United StatesContact: Annemarie VanceTaking people
About the trial
What the trial wants to find out
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
The 2 groups in the trial
- Elismetrep 10 mgTreatment being tested
Participants were randomised to receive elismetrep at a dose of 10 mg
Treatment: Elismetrep
- Elismetrep 20 mgTreatment being tested
Participants were randomised to receive elismetrep at a dose of 20 mg
Treatment: Elismetrep
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Plain-language title
- Long-term safety study of elismetrep for acute migraine attacksGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 2 November 2026